Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01775423 · ClinicalTrials.gov registry record · Phase 1

A Study of BBI608 in Adult Patients With Advanced Malignancies

A Phase 1 study, sponsored by Sumitomo Pharma America.

Completed
Registry status
Phase 1
Development phase
87
Enrollment target

NCT01775423 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 87 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01775423, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.

COMPLETED
Registry status
Phase 1
Development phase
87 participants
Enrollment target

Study Summary

This is an open label, single arm, dose escalation study of BBI608 in patients with advanced malignancies.

Interventions

  • DRUG BBI608

Trial Details

FieldValue
Enrollment Target 87 participants
Start Date 2009-03
Est. Completion 2015-08-06
Phase Phase 1

Sponsor

Sumitomo Pharma America

168 total trials

What the Registry Record Tells You About NCT01775423

The ClinicalTrials.gov registry entry for NCT01775423 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 87 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sumitomo Pharma America, which has 168 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which BBI608 is the first listed.

NCT01775423 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT01775423 about?

NCT01775423 is a clinical study titled "A Study of BBI608 in Adult Patients With Advanced Malignancies". This is an open label, single arm, dose escalation study of BBI608 in patients with advanced malignancies.

What is the current status of trial NCT01775423?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 87 participants. The study started on 2009-03. Estimated completion is 2015-08-06.

What interventions are being tested in trial NCT01775423?

The interventions under investigation include: BBI608 (DRUG).

Who is sponsoring clinical trial NCT01775423?

This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.